Phthalimide conjugation as a strategy for in vivo target protein degradation

Cited by (1,004)

Items 901–1,000 of 1,004

1. Recent Progress on Microtubule Degradation Agents
   Chufeng Zhang, Min Zhao, Guan Wang, Yong Li · 2023 · Journal of Medicinal Chemistry
2. Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo
   Yong Chen, Zihan Xia, Ujjwal Suwal, Pekka Rappu, Jyrki Heino, Olivier De Wever, Bruno G. De Geest · 2024 · Chemical Science
3. Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma
   Min Ai, Hulin Ma, Jianhua He, Fuyan Xu, Yue Ming, Zixia Ye, Qingquan Zheng, Dongdong Luo, Kai Yang, Jiao Li et al. · 2024 · European Journal of Medicinal Chemistry
4. Recruitment to the Proteasome Is Necessary but Not Sufficient for Chemically Induced, Ubiquitin-Independent Degradation of Native Proteins
   Madeline Balzarini, Joel Tong, Weijun Gui, Isuru M. Jayalath, Bin-Bin Schell, Thomas J. Kodadek · 2024 · ACS Chemical Biology
5. Elaboration of molecular glues that target TRIM21 into TRIMTACs that degrade protein aggregates
   Marc A Scemama de Gialluly, Anthony R. Allen, Elijah H Hayes, Patrick Zhuang, Ralston B. Goldfarb, Amanda N. Farrar, Yuriy Federov, Drew Adams · 2025 · Nature Communications
6. The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options
   Antonella Di Costanzo, Nunzio Del Gaudio, Lidio Conte, Lucia Altucci · 2020 · Cancers
7. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells
   Sarah D. Mahan, Kristin M. Riching, Marjeta Urh, Danette L. Daniels · 2021 · Methods in molecular biology
8. 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
   Yuqian Yan, Jingwei Shao, Donglin Ding, Yunqian Pan, Phuc Tran, Wei Yan, Zhenyu Wang, Hongyu Li, Haojie Huang · 2022 · Chemical Communications
9. Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications
   Arvind Negi, Kavindra Kumar Kesari, Anne Sophie Voisin‐Chiret · 2022 · Applied Sciences
10. Facilitating the development of molecular glues: Opportunities from serendipity and rational design
    Weiqing Jiang, Yunhan Jiang, Youfu Luo, Wenliang Qiao, Tao Yang · 2023 · European Journal of Medicinal Chemistry
11. Discovery and Characterization of Active CBP/EP300 Degraders Targeting the HAT Domain
    Iván Cheng‐Sánchez, Katherine A. Gosselé, Leonardo Palaferri, Mariia S. Kirillova, Cristina Nevado · 2024 · ACS Medicinal Chemistry Letters
12. Discovery of potent PROTAC degraders of Pin1 for the treatment of acute myeloid leukemia
    Yunkai Shi, Minmin Liu, Mengna Li, Yiwen Mao, Jingkun Ma, Ruikai Long, Miaomiao Xu, Yaxi Yang, Wenlong Wang, Yubo Zhou et al. · 2024 · Chemical Science
13. Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein
    Norihito Shibata, Nobumichi Ohoka, Takayuki Hattori, Mikihiko Naito · 2019 · Chemical and Pharmaceutical Bulletin
14. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
    Samir H. Barghout · 2020 · Anti-Cancer Agents in Medicinal Chemistry
15. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
    Daniela Tomaselli, Nicola Mautone, Antonello Mai, Dante Rotili · 2020 · European Journal of Medicinal Chemistry
16. Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay
    Wenwei Lin, Yongtao Li, Jaeki Min, Jiuyu Liu, Lei Yang, Richard E. Lee Jr., Taosheng Chen · 2020 · Bioconjugate Chemistry
17. A strategy to assess the cellular activity of E3 ligase components against neo-substrates using electrophilic probes
    Pinch, Benika J., Buckley, Dennis L., Gleim, Scott, Brittain, Scott M., Tandeske, Laura, D'Alessandro, Pier Luca, Hauseman, Zachary J., Lipps, Jennifer, Xu, Lei, Harvey, Edward P. et al. · 2022 · Cell Chemical Biology
18. High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules
    Ye Tian, Maximilian Seifermann, Liana Bauer, Charlotte Luchena, Janne J. Wiedmann, S. Schmidt, Alexander Geisel, Sergii Afonin, Julius Höpfner, Marius Brehm et al. · 2024 · Small
19. Development and validation of LC-MS/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471)
    Janis Niessen, Jenny M. Nilsson, Karsten Peters, Anura S. Indulkar, Thomas B. Borchardt, Mirko Koziolek, Hans Lennernäs, David Dahlgren, Mikael Hedeland · 2024 · Journal of Pharmaceutical and Biomedical Analysis
20. BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression
    Yanjie Kong, Tianlong Lan, Luzhen Wang, Gong Chen, Wenxin Lv, Hailin Zhang, Chengang Zhou, Xiuyun Sun, Wenjing Liu, Huang Haihui et al. · 2024 · Oncogene
21. Discovery of an LSD1 PROTAC degrader
    Amir Hosseini, Xing Qiu, Yan Xiong, Ki Him Nicholas Chiang, Jerrel Lewis Catlett, Ines H. Kaltheuner, Zhijie Deng, Sudipta Ghosh, Yang Shi, Jian Jun Jin · 2025 · Proceedings of the National Academy of Sciences
22. DCAF16-Based Covalent Degradative Handles for the Modular Design of Degraders
    Lauren M. Orr, Sydney J. Tomlinson, Hannah R. Grupe, Melissa Lim, Emily Ho, Halime Yilmaz, Grace Zhou, Barbara Leon, James A. Olzmann, Daniel K. Nomura · 2025 · ACS Central Science
23. Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay
    Wenwei Lin, Yongtao Li, Lei Yang, Taosheng Chen · 2020 · ACS Omega
24. The Vital Role of Proteomics in Characterizing Novel Protein Degraders
    Andrew X. Zhang, Katelyn B. Cassidy, Göran Dahl, Kévin Moreau, Fiona Pachl, Andrea M. Zuhl · 2021 · SLAS DISCOVERY
25. Computational strategies for PROTAC drug discovery
    Jia Wu, Wanhe Wang, Chung‐Hang Leung · 2023 · Acta Materia Medica
26. Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells
    Thamir M. Ismail, Rachel G. Crick, Min Du, Uma Shivkumar, Andrew J. Carnell, Roger Barraclough, Guozheng Wang, Zhenxing Cheng, Weiping Yu, Angela M. Platt-Higgins et al. · 2023 · Biomolecules
27. Novel therapeutic strategies for MLL-rearranged leukemias
    Nok-Hei Mickey Wong, Chi Wai Eric So · 2020 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
28. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective
    Xia Wu, Yangyang Meng, Lei Liu, Guowei Gong, Haotian Zhang, Yunlei Hou, Chunyang Liu, Di Wu, Mingze Qin · 2021 · Bioorganic & Medicinal Chemistry
29. A Chemical Toolbox for Labeling and Degrading Engineered Cas Proteins
    Rodrigo A. Gama-Brambila, Jie Chen, Yasamin Dabiri, Georg Tascher, Václav Němec, Christian Münch, Guangqi Song, Stefan Knapp, Xinlai Cheng · 2021 · JACS Au
30. Identification of PDE6D as a potential target of sorafenib via PROTAC technology
    Yang Li, Qingshi Meng, Ping Wang, Xiaolei Liu, Qiuyu Fu, Yuting Xie, Yu Zhou, Xiangbing Qi, Niu Huang · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
31. Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective
    Xiujin Chang, Fangui Qu, Chunxiao Li, Jingtian Zhang, Yanqing Zhang, Yuanyuan Xie, Zhongpeng Fan, Jinlei Bian, Jubo Wang, Zhiyu Li et al. · 2024 · Medicinal Research Reviews
32. Lysosome–targeting chimeras containing an endocytic signaling motif trigger endocytosis and lysosomal degradation of cell-surface proteins
    Tong Fang, Zhenting Zheng, Na Li, Yishu Zhang, Jing Ma, Chengyu Yun, Xiaoqing Cai · 2024 · Chemical Science
33. Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
    Meiyue Tang, Ming Gong, Xiaoliang Liu, Tiantian Zhang, Zhenghua Liu, Dandan Song · 2025 · European Journal of Medicinal Chemistry
34. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development
    Moyang Lv, Weichao Hu, Shengwei Zhang, Lijiao He, Changjiang Hu, Shiming Yang · 2022 · Cancer Letters
35. Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits
    Arvind Negi, Charline Kieffer, Anne Sophie Voisin‐Chiret · 2022 · ChemistrySelect
36. Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
    Jing Liu, Yunhua Peng, Hiroyuki Inuzuka, Wenyi Wei · 2022 · Seminars in Cancer Biology
37. Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation
    Patrick H. Gross, Katie J. Sheets, Noël A. Warren, Saptarshi Ghosh, Rebekah E. Varghese, Katherine E. Wass, Karteek Kadimisetty · 2022 · Biochemical and Biophysical Research Communications
38. Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies
    Andrey Rubanov, Pietro Berico, Eva Hernando · 2022 · Cancers
39. PROTAC Nanoplatform with Targeted Degradation of NAD(P)H:Quinone Oxidoreductase 1 to Enhance Reactive Oxygen Species-Mediated Apoptosis
    Haili Zhang, Xiao Xu, Dan Yan, Chunlin Ren, Jinghan Zhang, Mengzhen Gu, Yun Wang, Peiye Wu, Zhongrui Li, Lingyi Kong et al. · 2023 · ACS Applied Materials & Interfaces
40. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors
    Amit Kumar, Luni Emdad, Paul B. Fisher, Swadesh Kumar Das · 2023 · Advances in cancer research
41. Enantioselective Degrader for Elimination of Extracellular Aggregation-Prone Proteins hIAPP Associated with Type 2 Diabetes
    Zhenqi Liu, Dongqin Yu, H. L. Song, Miles L. Postings, Peter Scott, Zhao Wang, Jinsong Ren, Xiaogang Qu · 2023 · ACS Nano
42. Novel approaches to targeting BRD4
    Olesya A. Kharenko, Henrik Claus Hansen · 2017 · Drug Discovery Today Technologies
43. Cereblon suppresses the formation of pathogenic protein aggregates in a p62-dependent manner
    Liang Zhou, Zongbing Hao, Guanghui Wang, Guoqiang Xu · 2017 · Human Molecular Genetics
44. Advanced proteomics approaches to unravel protein homeostasis
    Paola Grandi, Marcus Bantscheff · 2019 · Drug Discovery Today Technologies
45. The Present and Future of Novel Protein Degradation Technology
    Liwen Xia, Wei Liu, Yinsen Song, Hai‐Liang Zhu, Yongtao Duan · 2019 · Current Topics in Medicinal Chemistry
46. A 3-hydroxythalidomide-based fluorescent probe for detection of fluoride in water sample and bioimaging in living cells
    Xiaolei Liu, Zhen Yang, Xiaofeng Yang, Yu Cui, Guoxin Sun · 2019 · Dyes and Pigments
47. Ubiquitination in cancer stem cell: roles and targeted cancer therapy
    Liu Liu, Shasha Yin, Charles Brobbey, Wenjian Gan · 2020 · STEMedicine
48. Molecular Epigenetics: Chemical Biology Tools Come of Age
    John D. Bagert, Tom W. Muir · 2021 · Annual Review of Biochemistry
49. Targeted protein modification as a paradigm shift in drug discovery
    Amirian, Roshanak, Azadi Badrbani, Mehdi, Izadi, Zhila, Samadian, Hadi, Bahrami, Gholamreza, Sarvari, Sajad, Abdolmaleki, Sara, Nabavi, Seyed Mohammad, Derakhshankhah, Hossein, Jaymand, Mehdi · 2023 · European Journal of Medicinal Chemistry
50. Functional investigations of p53 acetylation enabled by heterobifunctional molecules
    Chen, Li-Yun, Singha Roy, Soumya Jyoti, Jadhav, Appaso M., Wang, Wesley W., Chen, Pei-Hsin, Bishop, Timothy, Erb, Michael A., Parker, Christopher G. · 2024 · ACS Chemical Biology
51. Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
    Gregory S. Parker, Julia I. Toth, Sarah Fish, Gabrielle Blanco, Taylor Kampert, Xiaoming Li, Linette Yang, Craig R. Stumpf, Kenneth Steadman, Aleksandar Jamborcic et al. · 2024 · Molecular Cancer Therapeutics
52. Phthalimides: developments in synthesis and functionalization
    Fatemeh Doraghi, Mohammad Hossein Morshedsolouk, Nawrooz Ali Zahedi, Bagher A. Larijani, Mohammad Reza Mahdavi · 2024 · RSC Advances
53. Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge
    Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang · 2025 · Journal of Molecular Biology
54. Small-Molecule HSP27 Inhibitor Abolishes Androgen Receptors in Glioblastoma
    Yaxin Li, Cody M. Orahoske, Werner J. Geldenhuys, Asmita Bhattarai, Abboud Sabbagh, Viharika Bobba, Fatma M. Salem, Wenjing Zhang, Girish C. Shukla, Justin Durla Lathia et al. · 2021 · Journal of Medicinal Chemistry
55. Protein phase separation and its role in chromatin organization and diseases
    Jiaqi Li, Yao Zhang, Xi Chen, Lijuan Ma, Pilong Li, Haijie Yu · 2021 · Biomedicine & Pharmacotherapy
56. Iron-catalyzed hydroaminocarbonylation of alkynes to produce succinimides with NH4HCO3
    Zijun Huang, Changsheng Tang, Zilong Chen, Shaofeng Pi, Zheng-De Tan, Jiyong Deng, Yuehui Li · 2021 · Journal of Catalysis
57. Huntingtin Ubiquitination Mechanisms and Novel Possible Therapies to Decrease the Toxic Effects of Mutated Huntingtin
    Annarita Fiorillo, Veronica Morea, Gianni Colotti, Andrea Ilari · 2021 · Journal of Personalized Medicine
58. Human Cytomegalovirus IE2 Both Activates and Represses Initiation and Modulates Elongation in a Context-Dependent Manner
    Christopher B. Ball, Ming Li, Mrutyunjaya Parida, Qiaolin Hu, Deniz Ince, Geoffrey Collins, Jeffery L. Meier, David H. Price · 2022 · mBio
59. PROTAC antibiotics: the time is now
    Jickky Palmae Sarathy, Courtney C. Aldrich, Mei‐Lin Go, Thomas Dick · 2023 · Expert Opinion on Drug Discovery
60. ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas
    Baishan Jiang, David M. Weinstock, Katherine A. Donovan, Hong-Wei Sun, Ashley Wolfe, Sam Amaka, Nicholas L. Donaldson, Gongwei Wu, Yuan Zhu Jiang, Ryan A. Wilcox et al. · 2023 · Cell chemical biology
61. Kinetic Modeling of PROTAC‐Induced Protein Degradation
    Hongtao Zhao, Frank Narjes · 2023 · ChemMedChem
62. Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
    Xiaoyu Zhang, Benjamin F. Cravatt · 2024 · Annual Review of Cancer Biology
63. Facile and sensitive Hg2+ fluorescent probe based on repurposed molecular glue (3-hydroxythalidomide) and bioimaging in HeLa cells
    Xiaolei Liu, Hui Ma, Liang Xue, Xiujing Peng, Deli Li, Xuchuan Jiang · 2025 · Microchemical Journal
64. Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold
    David Remillard, Dennis L. Buckley, Hyuk‐Soo Seo, Fleur M. Ferguson, Sirano Dhe‐Paganon, James E. Bradner, Nathanael S. Gray · 2019 · ACS Medicinal Chemistry Letters
65. Challenges and Opportunities in NUT Carcinoma Research
    Bin Gu, Maxwell Hakun · 2021 · Genes
66. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4
    Xiang Wang, Qiwei Wang, Kai Ran, Jing Ren, Yaojie Shi, Luoting Yu · 2021 · Bioorganic Chemistry
67. Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold
    Jingjing Chen, Huixin He, Aihuan Wei, Yalei Li, Gang Cheng, Hui Qin, Hanyue Zhong, Hong‐Chun Liu, Meiyu Geng, Aijun Shen et al. · 2022 · European Journal of Medicinal Chemistry
68. Trends in small-molecule probes for lipid droplets
    Yaochen Tu, Wenjie Zhang, Jiaqian Yan, Miaomiao Wang, Bubin Xu, Yusheng Xie · 2025 · TrAC Trends in Analytical Chemistry
69. Characterization of cereblon-dependent targeted protein degrader by visualizing the spatiotemporal ternary complex formation in cells
    Tomohiro Kaji, Hiroshi Koga, Mutsumi Kuroha, Toshihiko Akimoto, Kenji Hayata · 2020 · Scientific Reports
70. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms
    Natalie Cheng Chen, Gautam M. Borthakur, Naveen Pemmaraju · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
71. Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation
    Inchul You, Katherine A. Donovan, Noah M. Krupnick, Andrew S. Boghossian, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Eric S. Fischer, Eric S. Wang, Nathanael S. Gray · 2022 · Cell chemical biology
72. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
    Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Bowen Li, Mei Yang, Edouard Collins Nice, Huili Zhu, Canhua Huang · 2023 · European Journal of Medicinal Chemistry
73. Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities
    Xiawen Dang, Ji‐Long Duan, Emily Ye, Nian-Dong Mao, Renren Bai, Xinglu Zhou, Xiang‐Yang Ye · 2023 · Bioorganic Chemistry
74. Role of BET proteins in castration-resistant prostate cancer
    Ester Fernández‐Salas, Shaomeng Wang, Arul M. Chinnaiyan · 2016 · Drug Discovery Today Technologies
75. BET proteins: Investigating BRDT as a potential target for male contraception
    Andrea J. Wisniewski, Gunda I. Georg · 2020 · Bioorganic & Medicinal Chemistry Letters
76. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules
    Yuqing Liang, Kutty Selva Nandakumar, Kui Cheng · 2020 · Biochemical Pharmacology
77. Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability
    Cyrille S. Kounde, Edward W. Tate · 2020 · Journal of Medicinal Chemistry
78. Cytomegalovirus late transcription factor target sequence diversity orchestrates viral early to late transcription
    Ming Li, Qiaolin Hu, Geoffrey Collins, Mrutyunjaya Parida, Christopher B. Ball, David H. Price, Jeffery L. Meier · 2021 · PLoS Pathogens
79. PHOTACs Enable Optical Control of Protein Degradation
    Martin Reynders, Dirk H. Trauner · 2021 · Methods in molecular biology
80. Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations
    Jaebong Jang, Ciric To, Dries J.H. De Clercq, Eunyoung Park, Charles M. Ponthier, Bo Hee Shin, Mierzhati Mushajiang, Radosław P. Nowak, Eric S. Fischer, Michael J. Eck et al. · 2020 · Angewandte Chemie
81. Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1
    Qilong Zhou, Wei Wu, Kaimin Jia, Guangyan Qi, Xiuzhi Susan Sun, Ping Li · 2022 · European Journal of Medicinal Chemistry
82. A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination
    Ellen F. Vieux, Roman V. Agafonov, Lydia Emerson, Marta Isasa, Richard W. Deibler, Jeffrey R. Simard, David Cocozziello, Brendon Ladd, Linda Lee, Heng Li et al. · 2021 · SLAS DISCOVERY
83. Unveiling the hidden interactome of CRBN molecular glues with chemoproteomics
    Kheewoong Baek, Rebecca J. Metivier, Shourya S. Roy Burman, Jonathan W. Bushman, Hojong Yoon, Ryan J. Lumpkin, Dinah M. Abeja, Megha Lakshminarayan, Hong Yue, Samuel Ojeda et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
84. Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation
    Zhijie Deng, Jerrel Lewis Catlett, Youngeun Lee, Qiong Di Wu, Zhongli Xu, Ling Xie, Xian Chen, Yan Xiong, H. Ümit Kanıskan, Jian Jun Jin · 2025 · Journal of Medicinal Chemistry
85. Chemoproteomics Enabled Discovery of Selective Probes for NuA4 Factor BRD8
    David Remillard, Nikolas A. Savage, Alexia T. Kedves, Joshiawa Paulk, Xin Chen, F. García, M.J. Romanowski, Patricia A. Horton, Jason Murphy, Markus Schirle et al. · 2021 · ACS Chemical Biology
86. Lysosome and related protein degradation technologies
    Hongmei Zheng, Gangjian Li, Jingli Min, Xiangwei Xu, Wenhai Huang · 2023 · Drug Discovery Today
87. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
    Kai Wang, Meixu Jiang, Huimin Liu, Chen Meng, Mengyuan Li, Haibin Lu · 2024 · Bioorganic Chemistry
88. Discovery of a NCOA4 Degrader for Labile Iron-Dependent Ferroptosis Inhibition
    Jianai Ji, Yuhui Jin, Sinan Ma, Yuxuan Zhu, Xinyu Bi, Qidong You, Zhengyu Jiang · 2024 · Journal of Medicinal Chemistry
89. Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia
    Angelo Aguilar, Jiuling Yang, Yangbing Li, Donna McEachern, Liyue Huang, Stevenchoukry Razzouk, Shaomeng Wang · 2024 · Journal of Medicinal Chemistry
90. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
    Stefanie Lindner, Christian Steinebach, Hannes Kehm, Martin Mangold, Michael Gütschow, Jan Krönke · 2019 · Journal of Visualized Experiments
91. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine
    Tomomi Sato, Takumi Ito, Hiroshi Handa · 2021 · Frontiers in Cell and Developmental Biology
92. Key regulators of sensitivity to immunomodulatory drugs in cancer treatment
    Shichao Wang, Zhiyue Li, Shaobing Gao · 2021 · Biomarker Research
93. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases
    Liang Zhou, Guoqiang Xu · 2022 · Journal of Molecular Biology
94. Synthesis and evaluation of RNase L-binding 2-aminothiophenes as anticancer agents
    Jimin Hwang, Xiaqiu Qiu, Lydia Borgelt, Neele Haacke, Laurin Kanis, Stavroula Petroulia, Raphael Gasper, Damian Schiller, Philipp Lampe, Sonja Sievers et al. · 2022 · Bioorganic & Medicinal Chemistry
95. BET inhibitors: an updated patent review (2018–2021)
    Huanhuan Chen, Zhenling Liu, Lili Zheng, Rongrong Wang, Lei Shi · 2022 · Expert Opinion on Therapeutic Patents
96. Role of bromodomain and extraterminal (BET) proteins in prostate cancer
    Adel Mandl, Mark Christopher Markowski, Michael Anthony Carducci, Emmanuel S. Antonarakis · 2023 · Expert Opinion on Investigational Drugs
97. Targeting protein function: the expanding toolkit for conditional disruption
    Amy E. Campbell, Daimark Bennett · 2016 · Biochemical Journal
98. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors
    James Joseph Driscoll, Magen Brailey · 2017 · Cancer and Metastasis Reviews
99. Bromodomain-Containing Protein 4: A Druggable Target
    Yingying Shi, Jingwen Liu, Yuanyuan Zhao, Jiaoxian Cao, Yiming Li, Fujiang Guo · 2019 · Current Drug Targets
100. DNA Framework-Based Lysosome-Targeting Chimeras: Intracellular ATP-Facilitated Extracellular Protein Degradation
     Yujun Ning, Bin Li, Chen Wu, Li Feng, Xuedong Huang, Baohong Liu · 2025 · ACS Nano